| Literature DB >> 28104906 |
Annette T Byrne1, Denis G Alférez2, Frédéric Amant3,4, Daniela Annibali3, Joaquín Arribas5,6, Andrew V Biankin7, Alejandra Bruna8, Eva Budinská9, Carlos Caldas8, David K Chang7, Robert B Clarke2, Hans Clevers10, George Coukos11, Virginie Dangles-Marie12, S Gail Eckhardt13, Eva Gonzalez-Suarez14, Els Hermans3, Manuel Hidalgo15, Monika A Jarzabek1, Steven de Jong16, Jos Jonkers17, Kristel Kemper17, Luisa Lanfrancone18, Gunhild Mari Mælandsmo19, Elisabetta Marangoni20, Jean-Christophe Marine21, Enzo Medico22, Jens Henrik Norum19, Héctor G Palmer23, Daniel S Peeper17, Pier Giuseppe Pelicci18, Alejandro Piris-Gimenez23, Sergio Roman-Roman20, Oscar M Rueda8, Joan Seoane5,6, Violeta Serra23, Laura Soucek5, Dominique Vanhecke11, Alberto Villanueva24, Emilie Vinolo25, Andrea Bertotti22, Livio Trusolino22.
Abstract
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28104906 DOI： 10.1038/nrc.2016.140
Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716